'bladder cancer recurrent', which were identified according to the Medical Dictionary for Regulatory Activities (MedDRA) (such information was also presented in electronic supplementary material (ESM) Table 2 of our article) [3] . Hence, the number of incident cases of bladder cancer in our article was correctly extracted from ClinicalTrials.gov, with the current database for the EMPA-REG OUTCOME Trial (ClinicalTrial.gov registration no. NCT01131676, accessed 9 August 2017) still showing six cases of bladder cancer, two cases of bladder transitional cell carcinoma, and one recurrent case of bladder cancer in the empagliflozin groups, and zero cases in the placebo group (Table 1) .
We appreciate the updated data from the US FDA provided by Dr. Shaikh [1] , which is also highlighted in a second letter by Kohler et al [5] , although the crude comparisons of case numbers made in this second letter could be misleading owing to the small sample size [5] . Even based on the intention-totreat data or on-treatment data sets provided by Kohler and colleagues [5] , we still observed a non-significant trend towards increased risk of bladder cancer in the pooled empagliflozin groups compared with the placebo groups; the relative risks were 1.20 (95% CI 0.42, 3.40) for the intentionto-treat data set and 1.83 (95% CI 0.51, 6.56) for the ontreatment data set. In addition, we feel it is important to note that the actual number of confirmed cancer cases would continue to accumulate during an extended post-trial period of the EMPA-REG OUTCOME Trial. However, given that participants in this trial were no longer receiving randomly assigned treatments, a crude comparison of accrued case numbers on an intention-to-treat basis tends to lead to a biased and incorrect estimate of drug effect owing to potential bias and confounding. Hence, we stand by our statement that 'there is some evidence suggesting that SGLT2 inhibitors (especially empagliflozin) might increase risk of bladder cancer', rather than conclusive evidence demonstrating a causal relationship.
Given the rapidly increasing use of SGLT2 inhibitors, future large long-term randomised trials, post-trial observational studies and real-world evidence are required to monitor the long-term safety of SGLT2 inhibitors regarding the risk of specific cancer types, especially bladder cancer.
